SK Life Science Labs
Larry Jolivette is a seasoned professional in the pharmaceutical industry, currently serving as Vice President and Head of DMPK and Toxicology at SK Life Science Labs since November 2021. Prior to this role, Larry Jolivette held the position of Sr. Director of DMPK at GlaxoSmithKline from July 2001 to November 2021, where responsibilities included leading DMPK initiatives and future pipeline discovery. Larry Jolivette earned a PhD in Pharmacology from the University of Rochester School of Medicine and Dentistry between 1995 and 2001 and holds a BS in Chemistry from Southern University, obtained from 1992 to 1995.
This person is not in any teams
SK Life Science Labs
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, is a U.S. biotech company focused on the discovery of transformative medicines through targeted protein degradation (TPD). We discover and develop therapies through precise degradation of disease-causing proteins. Our team takes a target-centric approach through AI enabled target identification. Our core TPD platform, built upon a strong TPD knowledge base, novel E3 ligands & linkers, and machine-learning based ternary complex modeling, is further complemented by a proprietary MOPED™ molecular glue platform. SK Life Science Labs integrates innovative platforms with deep drug-hunting expertise to defeat disease and improve patients’ lives. View our community guidelines here: http://bit.ly/3REsFKU